31 results about "Tetanus" patented technology

1. Name of this design product: Skin Test Judgment Ruler. 2. Application of this design: This design is used for skin tests of penicillin, cephalosporins, tetanus and tuberculin. 3. The key design feature of this product is its pattern. 4. The image or photograph that best illustrates the design's key features: the front view. 5. This design is a thin product, so the left view is omitted; this design is a thin product, so the right view is omitted; this design is a thin product, so the top view is omitted; this design is a thin product, so the bottom view is omitted.

The invention discloses a recombinant tetanus toxin protein rTT as well as a preparation method and application thereof, the recombinant protein sequentially contains a His tag, a modified exogenous polypeptide and two tetanus toxin fragments connected in series through flexible polypeptides from the N end to the C end, the two tetanus toxin fragments connected in series form two intramolecular disulfide bonds in a molecule through double mutation, and the tetanus toxin fragments are connected in series through flexible polypeptides. Coding nucleotide of the recombinant protein is expressed by escherichia coli BL21 (DE3), induced at low temperature and purified, and target protein with the purity larger than or equal to 95% can be obtained. A subunit vaccine prepared from the protein and a two-way oil adjuvant ISA201 enables mice to achieve 100% protection under 100 LD50 challenge dose, the protection effect is better than that of truncated tetanus toxin heavy chain fragment TTc protein, and the recombinant protein can be used for tetanus prevention vaccines and serological diagnostic reagents.

Disclosed in the present invention is a pharmaceutical combination comprising an adsorbed tetanus vaccine and an antibody or an antigen-binding fragment thereof against tetanus toxin. The pharmaceutical combination is used for preventing and / or treating tetanus.

The present invention relates to a nucleic acid molecule for modulating neuromuscular transmission, said nucleic acid molecule comprising a sequence encoding one or more motor endplate receptors or fragments thereof. The present invention further relates to a fusion protein, preferably comprising one or more features of one or more of the foregoing Claims, said fusion protein comprising a motor endplate receptor and / or fragments thereof, wherein said motor endplate receptor is an acetylcholine receptor (AChR), a muscle-specific tyrosine kinase (MuSK) receptor, and / or a glutamate receptor, and / or fragments thereof, and / or a neurotoxin, wherein said neurotoxin is botulinum toxin (BoNT) and / or tetanus toxin.

The invention discloses a preparation method of a proteoglycan protein conjugate carrying a specified connection site. The method comprises the following steps: carrying out recombinant expression on a recombinant tetanus toxin heavy chain C fragment rTTHc containing a Sortase A 7M ligase recognition sequence, introducing O, O '-(ethane-1, 2-diyl) bis (hydroxylamine) as a nucleophilic reagent into the C tail end of the rTTHc under the action of ligase Sortase A 7M, and carrying out specific condensation reaction on the C tail end of the rTTHc as a unique chemical reaction site and polysaccharide carrying an aldehyde group functional group to obtain the tetanus toxin heavy chain C fragment rTTHc. Therefore, polysaccharide protein conjugates with definite polysaccharide and protein connection sites are produced. According to the invention, the problem that the key antigen epitope of the carrier protein and the heterogeneity of the product are possibly damaged by the traditional random modification strategy is solved, the antigen epitope of the carrier protein is prevented from being damaged to a great extent, and a reliable technical scheme is provided for preparing the polysaccharide conjugate vaccine with high quality and high immunogenicity.

The invention provides an anti-tetanus antibody as well as preparation and application thereof, and relates to the field of antibodies. The amino acid sequence of the tetanus-resistant antibody heavy chain CDR is as shown in SEQ ID NO: 1-3; the amino acid sequence of the light chain CDR of the antibody is as shown in SEQ ID NO: 4-6. The antibody disclosed by the invention is high in activity and affinity, and has the application prospect of preparing a medicine for preventing and / or treating tetanus or a product for detecting the tetanus toxin level with a non-diagnostic purpose and the like.

The present disclosure provides an anti-tetanus toxin neutralizing antibody as a new generation of tetanus passive immunization preparation. The antibody can be fully human, which can specifically bind to full-length tetanus toxin and its AB fragment, has high affinity, high specificity, small toxic side effects, avoids the problems of large adverse reactions and short half-life of animal-derived monoclonal antibodies, and is prepared in large quantities by mammalian cells, and has clear and stable components.

The invention discloses a technology for removing viruses from tetanus human immune globulin through a nano film. The process comprises the following steps: pretreating a feed liquid, so that the protein concentration of the feed liquid is 50-60g / L, the pH is 3.8-4.4, and the feed liquid contains 90-110g / L maltose and 50-150mmol / L sodium chloride; then, the feed liquid is subjected to two-stage filtration through a 0.1-micron nylon pre-filtration membrane bag with negative charges and a 20-nm regenerated cellulose (RC) virus removal membrane bag in sequence. According to the process, through optimizing the physical and chemical state of the feed liquid and the synergistic effect of the feed liquid and the functionalized filter membrane, the protein aggregation is effectively inhibited, the membrane pollution is reduced, the virus removal effect is ensured not to be lower than 4log10, the protein load of the RC membrane is remarkably improved to be more than 200L / m, and the product purity is more than or equal to 98%. The invention solves the technical problems of low flux and easy blockage of high-concentration immune globulin in small-aperture virus removal filtration, and is suitable for efficient, safe and large-scale production of blood products.

Disclosed in the present invention is a formulation containing an anti-tetanus toxin antibody, wherein the formulation comprises the anti-tetanus toxin antibody at a concentration of 1-100 mg / mL, and has a pH of 5.0-7.0; and optionally, the formulation further comprises one or more of a surfactant, a pH regulator, a protein protective agent, and an osmotic pressure regulator. The formulation provided by the present invention can effectively maintain the stability of the antibody, so that the antibody is not liable to aggregate, thereby preventing oxidation, denaturation and degradation. In addition, the formulation also maintains the high titer of the antibody against tetanus toxin, and thus has the high biological activity required for preventing or treating tetanus.

Provided are a bispecific antibody and a monoclonal antibody for a tetanus toxin, and uses of the antibodies. The bispecific antibody contains a first antigen-binding fragment and a second antigen-binding fragment which bind to different epitopes of the tetanus toxin, and has activity of neutralizing the tetanus toxin. The monoclonal antibody binds to the tetanus toxin, and has activity of neutralizing the tetanus toxin.

This utility model relates to the technical field of human immunoglobulin preparation devices, and discloses a sampling device for preparing tetanus human immunoglobulin. It includes a sampling cylinder with a low-temperature storage mechanism on its outer wall and an automatic sampling mechanism. The low-temperature storage mechanism includes a first support ring, a supporting outer cylinder fixedly mounted at the bottom of the first support ring, and a second support ring fixedly mounted at the bottom of the supporting outer cylinder. Through the design of the low-temperature storage mechanism, this utility model can store a low-temperature medium in the cavity formed by the first support ring, the supporting outer cylinder, the second support ring, and the copper inner cylinder. The low-temperature medium can pass through the copper inner cylinder to cool the inner cavity of the sampling cylinder, thus achieving the function of low-temperature storage of the sample inside the sampling cylinder. This avoids the problem of sample deterioration during storage due to high ambient temperatures, ensuring the accuracy of biochemical analysis.

Disclosed in the present invention is a compound adjuvant combined vaccine, comprising an immunogenic composition and a compound adjuvant. The immunogenic composition comprises a pertussis antigen, a diphtheria antigen and a tetanus antigen; and the compound adjuvant is composed of an aluminum adjuvant and a TLR9 receptor agonist. Further disclosed in the present invention is a use of the compound adjuvant in the preparation of the compound adjuvant combined vaccine for preventing pertussis, diphtheria and tetanus in a subject.

The application discloses a preparation containing an anti-tetanus toxin antibody, the preparation containing the anti-tetanus toxin antibody at a concentration of 1-100 mg / mL and having a pH of 5.0-7.0; and optionally, the preparation further contains one or more of a surfactant, a pH regulator, a protein protective agent and an osmotic pressure regulator. The preparation provided by the application can effectively maintain the stability of the antibody, so that the antibody is not prone to aggregation, oxidation, denaturation and degradation; in addition, the antibody has a high titer of anti-tetanus toxin and high bioactivity required for preventing or treating tetanus.

This invention belongs to the field of veterinary biological products technology, specifically relating to a traditional Chinese medicine composition for improving plasma titer and protecting the liver in tetanus-immunized horses, and its application. The composition consists of the following herbs in parts by weight: Angelica sinensis 20-30 parts, Paeonia lactiflora 20-30 parts, Bupleurum chinense 15-20 parts, Atractylodes macrocephala 25-35 parts, Poria cocos 20-30 parts, and Artemisia capillaris 30-40 parts. Experiments show that the composition of this invention can increase the average IgG titer of culled horses with low titers (initial IgG titer 800-1200 IU / mL) by more than 250 IU / mL after an 18-week immunization cycle, far exceeding the predetermined target of 200 IU / mL. Simultaneously, it significantly increases the immunization pass rate (≥1300 IU / mL) of newly immunized horses from 73.3% in the control group to 93.3%, an absolute increase of 20 percentage points. Furthermore, the area under the IgG titer-time curve (AUC) is 1.3 times higher than that of the control group, indicating a significant increase in the cumulative antibody production throughout the immunization cycle. This invention improves the plasma titer of horses while also protecting the liver, and has good application prospects.

The invention provides a nanoparticle protein rePO-TTFC (at) LS as well as a preparation method and application thereof. The protein is composed of rePO (at) LS and a tetanus toxin C fragment TTFC. The recombinant protein SpyCatcher-rePO at LS disclosed by the invention is subjected to induced expression in escherichia coli in a soluble form. According to the present invention, the recombinant protein SpyCatcher-rePO (at) LS can be subjected to covalent binding with the recombinant protein reTTFC-SpyTag through the isopeptide bond so as to form the rePO-TTFC (at) LS duplex nanoparticle vaccine molecule, and the binding condition is simple; the nanoparticle protein can induce an animal body to generate high-level immune response and play an immune protection role, the response speed and protection efficiency of an antibody induced by the nanoparticle protein are obviously superior to those of a monomer rePO and a monomer reTTFC fusion protein, and the nanoparticle protein can be used for preventing and treating pseudomonas aeruginosa and tetanus at the same time.

Provided are an anti-tetanus toxin neutralizing antibody and the use thereof as a new-generation tetanus passive immunological preparation. The antibody can be a fully human antibody, has the characteristics of a high affinity, a high specificity, and few toxic side effects, and avoids the problems of strong adverse reactions and a short half-life of animal-derived monoclonal antibodies. Moreover, the antibody can be prepared on a large scale using mammalian cells, and has a clear and stable composition. On the basis of clinical requirements, the exploration and development of an anti-tetanus toxin neutralizing fully-human antibody as a new-generation tetanus passive immunological preparation has great medical value.

The invention discloses a preparation and test method of an immunosensor for tetanus toxin detection. The method comprises the following steps: respectively preparing a tetrachloroauric acid solution and a hexachloroplatinic acid solution, dropwise adding the tetrachloroauric acid solution and the hexachloroplatinic acid solution to the red copper sheet, and drying under an ultraviolet lamp to form a gold-platinum nanoparticle catalyst layer; placing the red copper sheet in a chamber of electron-assisted hot filament chemical vapor deposition system equipment for growing a gold platinum-vertical graphene electrode; dropwise adding a tetanus antibody solution and a bovine serum albumin solution into the gold platinum-vertical graphene electrode to obtain a gold platinum-vertical graphene electrode incubated with bovine serum albumin and a tetanus antibody; a tetanus toxin solution is taken and dropwise added to the gold platinum-vertical graphene electrode incubated with bovine serum albumin and tetanus antibodies, and the immunosensor for tetanus toxin detection is obtained. The method inhibits non-specific adsorption, stabilizes a base line, and supports tetanus toxin low-concentration quantification and subsequent application linkage.

The invention provides a pharmaceutical composition for preventing and / or treating tetanus as well as a preparation method and application of the pharmaceutical composition. The pharmaceutical composition comprises a recombinant tetanus toxin C fragment as a unique antigen component, an adjuvant and a solvent, wherein the adjuvant is selected from one or more of an aluminum adjuvant, a Toll-like receptor stimulant and saponin, preferably the aluminum adjuvant, and / or the solvent is selected from one or more of a phosphate buffer solution, a citrate buffer solution, a histidine salt buffer solution and a sodium chloride solution, preferably the phosphate buffer solution and / or the sodium chloride solution. The adopted recombinant tetanus natural C fragment (Hc) is non-toxic, formaldehyde inactivation is not needed, meanwhile, the possibility of toxicity reversion is avoided, and the pharmaceutical composition can induce mammals to generate high immune response against tetanus and has good immune persistence.

Provided is an application of an anti-tetanus toxin antibody in preventing or treating tetanus. The anti-tetanus toxin antibody is applied in a specific administration regimen, and can achieve the technical effects of being quicker to take effect and having a longer protection time than existing passive immunization agents, and can therefore effectively prevent or treat tetanus.

The application discloses a preparation and testing method of an immunosensor for detecting tetanus toxin. The method comprises the following steps: respectively preparing tetrachloroauric acid solution and hexachloroplatinic acid solution, and dropping the two solutions on a red copper sheet; after baking under an ultraviolet lamp, a gold platinum nanoparticle catalyst layer is formed; the red copper sheet is placed in a chamber of an electron-assisted hot-wire chemical vapor deposition system device, so as to grow a gold platinum-vertical graphene electrode; a tetanus antibody solution and a bovine serum albumin solution are dropped on the gold platinum-vertical graphene electrode, so that a gold platinum-vertical graphene electrode incubated with bovine serum albumin and tetanus antibody is obtained; a tetanus toxin solution is dropped on the gold platinum-vertical graphene electrode incubated with bovine serum albumin and tetanus antibody, so that an immunosensor for detecting tetanus toxin is obtained. The application can inhibit non-specific adsorption, stabilize a baseline, support low-concentration quantification of tetanus toxin, and connect subsequent applications.

The invention discloses a recombinant Marek's virus vector vaccine strain for expressing H9N2 subtype avian influenza virus HA protein and application of the recombinant Marek's virus vector vaccine strain, and belongs to the technical field of veterinary biological products. The amino acid sequence of the HA protein expressed by the recombinant Marek's virus vector vaccine strain is as shown in SEQ ID NO. 1. The amino acid sequence of the HA protein is obtained by modifying the 84th amino acid of the amino acid sequence shown as SEQ ID NO.2 into tryptophan from serine, eliminating the 82nd glycosylation site of the HA protein, replacing the signal peptide of the HA gene with the Ig lambda signal peptide of chicken, and adding GGGGS linker and one tetanus toxin T cell epitope to the carboxyl terminal of the HA protein. The vaccine strain is good in in-vitro proliferation characteristic, stable in genome heredity and capable of stably expressing HA protein, no side reaction or pathogenic effect exists after SPF chicken is immunized, 100% protection against H9N2 strain attack can be provided 21 days after immunization, and the problem that the immune protection blank period of other vaccines such as H9N2 inactivated vaccines is long is solved.

The present invention relates to a process of purifying a protein. Specifically, the present invention relates to a process of purification of a polyclonal antibody and / or antibody fragments. The present invention employs an adsorptive separation using anion exchange chromatography and cation exchange chromatography along with ultrafiltration and diafiltration to achieve high-purity antibody / or antibody fragments. The process provided in the present invention is applicable for polyclonal antibody and / or antibody fragments, which are associated with conditions but not limited to snake envenomation, scorpion envenomation, diphtheria infection, tetanus infection, rabies virus infection and gas gangrene infection due to Clostridium species.

The utility model relates to the technical field of filter presses, and discloses a filter press in tetanus human immune globulin production, which comprises a support, a filter press is mounted at the top end of the support, a flow regulating mechanism is arranged at the side end of the filter press, a plurality of filter frames are slidably connected from the top end to the inside of the filter press, and the filter frames are connected with the support. An insertion hole is formed in the side end of the top of each filter frame, a rectangular groove is formed in the top end of the filter press, circular grooves are formed in the side end of the rectangular groove at intervals, a rebound assembly is arranged in the rectangular groove, a limiting assembly used for fixing each filter frame is arranged at the outer end of the rebound assembly, and telescopic assemblies are arranged in the circular grooves. According to the utility model, through the matched arrangement of the rebound assembly, the limiting assembly and the telescopic assembly, the filter frame can be conveniently limited and fixed, and the condition that the filter frame is easy to loosen or is not completely inserted into the filter press is avoided, so that the normal use and the use effect of the filter frame and the filter plate are prevented from being influenced.

To provide an antidepressant with a broader range of therapeutic effects, fewer side effects, and a faster onset of action. [Solution] The C-terminal domain of the heavy chain of tetanus toxin (Hc-TeTx) provides therapeutic effects in motor dysfunction associated with Parkinson's disease (PD), and provides long-lasting antidepressant effects, and is therefore useful in treating and alleviating depression, particularly PD-comorbid depression. A method for treating and alleviating depression involves administering an effective amount of the C-terminal domain of the heavy chain of tetanus toxin (Hc-TeTx) to a subject in need. A method for treating or alleviating motor dysfunction associated with Parkinson's disease (PD) involves administering an effective amount of the C-terminal domain of the heavy chain of tetanus toxin (Hc-TeTx) to a subject in need.

The utility model relates to the technical field of centrifugal devices, and discloses a tetanus human immune globulin centrifugal device which comprises a centrifugal box, an annular groove is formed in the top end of an annular plate, a rotating mechanism is arranged on the inner side of the annular plate, a mounting groove is formed in the bottom end of a box cover, a pressing mechanism is arranged in the mounting groove, and the rotating mechanism is arranged on the inner side of the annular plate. The centrifugal box comprises a box cover, a centrifugal box body, a locking structure and a pressing mechanism, the bottom end of the box cover is provided with a rectangular groove, the rectangular groove is internally provided with a limiting mechanism used for fixing the pressing mechanism, and the outer side end of the box cover is provided with a fixing mechanism used for fixing the limiting mechanism. The sealing cover at the top end of the centrifugal tube can be conveniently pressed and fixed, so that when the rotating speed of the centrifugal device is high, the situation that the sealing cover of the centrifugal tube is unstable in sealing is not easily caused, liquid is prevented from being splashed out, and separation and purification of raw material plasma are prevented from being affected.

To provide a muscle electrostimulation device capable of effectively stimulating abdominal muscles.SOLUTION: A muscle electrostimulation device 1 for applying electrostimulation to a muscle, wherein the electrostimulation includes only a first output period in which a first electric signal for causing at least one of incomplete tetanus and complete tetanus in the muscle is output and a second output period in which a second electric signal for causing twitching in the muscle is output, and the first output period and the second output period are alternately repeated.SELECTED DRAWING: Figure 1

The invention discloses a gold-vertical graphene microelectrode and a preparation method and application thereof. The gold-vertical graphene microelectrode comprises a metal piece, a vertical graphene nanosheet is formed on the surface of the metal piece, and Au nanoparticles are embedded in the vertical graphene nanosheet. The BSA-Ab (at) gold-vertical graphene electrode comprises a gold-vertical graphene microelectrode, a tetanus antibody and bovine serum albumin, wherein the tetanus antibody and the bovine serum albumin are incubated on the gold-vertical graphene microelectrode. The BSA-Ab (at) gold-vertical graphene electrode is wide in tetanus toxin detection range and can be used for detecting the concentration of tetanus toxin in blood or serum.